{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:20:51Z","timestamp":1755224451592,"version":"3.43.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Thalamic ataxia syndrome is a rare but <jats:italic toggle=\"yes\">severely disabling<\/jats:italic> condition resulting from thalamic lesions, <jats:italic toggle=\"yes\">characterized by persistent motor incoordination that frequently fails to respond<\/jats:italic> to conventional rehabilitation therapies. <jats:italic toggle=\"yes\">Given the lack of effective treatment options and the profound impact on patients\u2019 quality of life, this study aimed to evaluate<\/jats:italic> the efficacy of local botulinum toxin type A (BoNT-A) injections <jats:italic toggle=\"yes\">as a potential breakthrough treatment<\/jats:italic> for improving motor control and daily living activities in patients with thalamic ataxia. <jats:italic toggle=\"yes\">This investigation represents the first clinical application of BoNT-A specifically targeting thalamic ataxia, offering new hope for treatment-resistant cases.<\/jats:italic>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 59-year-old female presented with a 6-month history of debilitating left limb movement disorder, including inability to lift the left upper limb, grasp objects, or perform essential daily activities such as eating and carrying a cup. Despite 5 months of <jats:italic toggle=\"yes\">intensive<\/jats:italic> rehabilitation, her symptoms showed minimal improvement, <jats:italic toggle=\"yes\">leaving her functionally dependent.<\/jats:italic>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with thalamic ataxia syndrome secondary to right thalamic hemorrhage, confirmed by cranial CT and MRI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received precisely targeted local BoNT-A injections (total 130U) into the affected upper limb muscles (deltoid, biceps brachii, flexor carpi radialis, flexor carpi ulnaris, pronator teres, extensor carpi radialis, and flexor digitorum superficialis) under dual ultrasound and electromyography guidance, ensuring optimal muscle selection and dosing accuracy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Three weeks postinjection, the International Cooperative Ataxia Rating Scale score decreased by 8 points (from 24 to 16), with the most significant improvement in dynamic function (upper limb ataxia subscores reduced from 18 to 10). The Fugl-Meyer Assessment Upper Extremity Scale increased by 6 points (from 52 to 58), particularly in hand coordination and speed tasks. The modified Barthel index improved by 9 points (from 85 to 94), enabling independent performance of previously difficult activities like self-feeding and cup handling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Local BoNT-A injections <jats:italic toggle=\"yes\">represent a novel and potentially transformative<\/jats:italic> treatment for thalamic ataxia syndrome, particularly in cases refractory to conventional therapies. These findings challenge current rehabilitation paradigms and highlight the need for further studies with larger cohorts to validate and expand upon these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000043136","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:01:17Z","timestamp":1752516077000},"page":"e43136","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Local injection of botulinum toxin type A in the treatment of thalamic ataxia syndrome: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[{"name":"Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yike","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Xie","sequence":"additional","affiliation":[{"name":"Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0550-4010","authenticated-orcid":false,"given":"Peichun","family":"Li","sequence":"additional","affiliation":[{"name":"Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.44.5.810","article-title":"The thalamic ataxia syndrome.","volume":"44","author":"Solomon","year":"1994","journal-title":"Neurology"},{"key":"R2-20250812","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000478975","article-title":"Combination treatment of low-frequency repetitive transcranial magnetic stimulation and intensive occupational therapy for ataxic hemiparesis due to thalamic hemorrhage.","volume":"9","author":"Urushidani","year":"2017","journal-title":"Case Rep Neurol"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"104682","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104682","article-title":"Botulinum Toxin Type A for upper limb spasticity in poststroke patients: a meta-analysis of randomized controlled trials.","volume":"29","author":"Jia","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/mds.23712","article-title":"Disappearance of essential tremor after stroke: which fiber of cerebellar loops is involved in posterior limb of the internal capsule?","volume":"26","author":"Mochizuki","year":"2011","journal-title":"Mov Disord"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2018.12.002","article-title":"Use of botulinum toxin in Parkinson\u2019s disease.","volume":"59","author":"Jocson","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/toxins12110691","article-title":"Sialorrhea in Parkinson\u2019s disease.","volume":"12","author":"Isaacson","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2169\/internalmedicine.55.5843","article-title":"Brain metabolic changes of cervical dystonia with spino cerebellar ataxia type 1 after botulinum toxin therapy.","volume":"55","author":"Kikuchi","year":"2016","journal-title":"Intern Med"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/toxins10070299","article-title":"Botulinum toxin for the treatment of hand tremor.","volume":"10","author":"Niemann","year":"2018","journal-title":"Toxins (Basel)"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","article-title":"A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.","volume":"56","author":"Brin","year":"2001","journal-title":"Neurology"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"600","DOI":"10.5334\/tohm.455","article-title":"Estimating change in tremor amplitude using clinical ratings: recommendations for clinical trials.","volume":"8","author":"Elble","year":"2018","journal-title":"Tremor Other Hyperkinet Mov (N Y)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:00:57Z","timestamp":1755018057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":10,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043136","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}